Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
Bluebird bio said it has set a list price of $3.1 million for its treatment, Lyfgenia, for the condition.
Both the therapies were approved by the U.S. health regulator earlier on Friday.
https://finance.yahoo.com/news/vertex-crispr-price-sickle-cell-181618940.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.